C3 and carcinoma: In the final steps of the proposed pipeline, we tested the promising proteins CFB and C3 as candidate carcinoma biomarkers, which in addition to being associated with the enriched complement and coagulation cascade pathway, were validated using immunoblotting, tissue microarrays and retrieved in the intersections of the feature selection methods.